title: Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.
abstract: Anaplastic thyroid carcinoma (ATC) is the rarest, but deadliest histologic type among thyroid malignancies, with a dismal median survival of 3-9 mo. Even though ATC accounts for less than 2% of all thyroid tumors, it is responsible for 14%-39% of thyroid carcinoma-related deaths. ATC clinically presents as a rapidly growing mass in the neck, associated with dyspnoea, dysphagia and vocal cord paralysis. It is usually locally advanced and often metastatic at initial presentation. For operable diseases, the combination of radical surgery with adjuvant radiotherapy or chemotherapy, using agents such as doxorubicin and cisplatin, is the best treatment strategy. Cytotoxic drugs for advanced/metastatic ATC are poorly effective. On the other hand, targeted agents might represent a viable therapeutic option. Axitinib, combretastatin A4, sorafenib and imatinib have been tested in small clinical trials of ATC, with a promising disease control rate ranging from 33% to 75%. Other clinical trials of targeted therapy for thyroid carcinoma are currently ongoing. Biological agents that are under investigation include pazopanib, gefitinib and everolimus. With the very limited therapeutic armamentarium available at the present time, targeted therapy constitutes an exciting new horizon for ATC. In future, biological agents will probably represent the standard of care for this aggressive malignancy, in the same fashion as it has recently occurred for other chemo-refractory tumors, such as kidney and hepatic cancer.
authors: Francesco Perri, Department of Skin, Musculoskeletal System and Head-neck, INT Foundation G. Pascale, Napoli 80131, Italy.
authors: Francesco
authors: F
authors: Perri
authors: Giuseppe Di
authors: GD
authors: Lorenzo
authors: Giuseppina Della Vittoria
authors: GD
authors: Scarpati
authors: Carlo
authors: C
authors: Buonerba
references: J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9
references: 17550961
references: J Biol Chem. 2004 Dec 24;279(52):54610-9
references: 15475567
references: Endocrinology. 2004 Mar;145(3):1031-8
references: 14607854
references: Laryngoscope. 2004 Mar;114(3):393-402
references: 15091208
references: J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21
references: 16849420
references: Cancer Lett. 2006 Jul 18;238(2):197-201
references: 16154259
references: Langenbecks Arch Surg. 2007 Jul;392(4):397-404
references: 17131154
references: Am J Clin Pathol. 1985 Feb;83(2):135-58
references: 2578727
references: Am J Pathol. 2004 Jul;165(1):35-52
references: 15215160
references: Ann Oncol. 2000 Sep;11(9):1083-9
references: 11061600
references: J Endocrinol Invest. 2000 Dec;23(11):755-61
references: 11194710
references: Int J Exp Pathol. 2002 Feb;83(1):21-38
references: 12059907
references: Cancer. 2005 Apr 1;103(7):1330-5
references: 15739211
references: Br J Cancer. 2002 Jun 17;86(12):1848-53
references: 12085174
references: J Neurooncol. 2003 Nov;65(2):107-18
references: 14686729
references: Ann Surg Oncol. 2008 Sep;15(9):2500-5
references: 18581185
references: Cancer Res. 2002 Jun 15;62(12):3408-16
references: 12067983
references: Br J Cancer. 1993 Oct;68(4):808-12
references: 8398712
references: Thyroid. 2002 Nov;12(11):953-61
references: 12490072
references: J Clin Endocrinol Metab. 2007 May;92(5):1938-42
references: 17327374
references: Mayo Clin Proc. 1985 Jan;60(1):51-8
references: 3965822
references: Thyroid. 2000 Jul;10(7):587-94
references: 10958311
references: J Endocrinol Invest. 1991 Jun;14(6):475-80
references: 1723086
references: Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43
references: 15519785
references: J Endocrinol. 2006 Nov;191(2):465-72
references: 17088416
references: Clin Cancer Res. 2006 Jan 15;12(2):600-7
references: 16428506
references: J Clin Oncol. 2005 Aug 20;23(24):5474-83
references: 16027439
references: Laryngoscope. 2007 Apr;117(4):674-9
references: 17429874
references: Cancer Res. 2000 Feb 1;60(3):650-6
references: 10676649
references: J Clin Oncol. 2005 Sep 1;23(25):5943-9
references: 16135465
references: Surg Today. 2004;34(5):394-8
references: 15108075
references: Head Neck. 1996 Jan-Feb;18(1):36-41
references: 8774920
references: Histopathology. 1991 Jan;18(1):11-8
references: 2013457
references: Clin Cancer Res. 2004 Dec 15;10(24):8594-602
references: 15623643
references: J Clin Oncol. 2004 Jan 1;22(1):115-9
references: 14701773
references: J Clin Oncol. 2008 Oct 10;26(29):4708-13
references: 18541897
references: Arch Otolaryngol Head Neck Surg. 1988 Jan;114(1):40-4
references: 3334817
references: Thyroid. 2002 Dec;12(12):1063-70
references: 12593719
references: Thyroid. 1995 Feb;5(1):67-73
references: 7787437
references: Radiother Oncol. 1999 Jan;50(1):33-8
references: 10225555
references: Ann Clin Lab Sci. 2003 Spring;33(2):192-9
references: 12817624
references: Int J Oncol. 2009 May;34(5):1353-62
references: 19360347
references: Am J Clin Oncol. 2002 Oct;25(5):442-6
references: 12393980
references: J Endocrinol. 1999 Apr;161(1):41-9
references: 10194527
references: Cancer. 1985 Nov 1;56(9):2155-60
references: 3902203
references: Oncogene. 2006 Apr 13;25(16):2304-17
references: 16331265
references: Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8
references: 7883548
references: J Clin Endocrinol Metab. 2005 Jun;90(6):3583-91
references: 15769983
references: Eur J Surg Oncol. 1992 Apr;18(2):83-8
references: 1582515
references: Endocrinology. 2006 Sep;147(9):4463-75
references: 16777971
references: Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
references: 16172168
references: Jpn J Cancer Res. 1996 Feb;87(2):113-6
references: 8609057
references: J Cancer Res Clin Oncol. 2005 Sep;131(9):585-90
references: 16021466
references: Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59
references: 16172161
references: Exp Cell Res. 2000 Aug 25;259(1):293-9
references: 10942601
references: J Surg Oncol. 1985 Aug;29(4):216-21
references: 4079403
references: Eur J Endocrinol. 2007 Apr;156(4):425-30
references: 17389456
references: J Clin Invest. 2006 Oct;116(10):2610-21
references: 17016557
references: Int J Cancer. 1991 Oct 21;49(4):558-61
references: 1917156
references: Horm Res. 1997;47(4-6):145-57
references: 9167946
references: Endocr Relat Cancer. 2006 Jun;13(2):401-13
references: 16728570
references: J Clin Endocrinol Metab. 2001 Apr;86(4):1769-77
references: 11297616
references: Endocr J. 2009;56(2):245-9
references: 19088401
references: Int J Cancer. 1996 Mar 1;65(5):620-6
references: 8598313
references: Br J Cancer Suppl. 1996 Jul;27:S86-8
references: 8763854
references: Cancer. 2001 Jun 15;91(12):2335-42
references: 11413523
references: Thyroid. 2009 Mar;19(3):233-40
references: 19265494
references: Thyroid. 2010 Jan;20(1):7-14
references: 20025538
references: Oncogene. 2005 Apr 18;24(17):2787-95
references: 15838515
references: J Clin Oncol. 2004 Jun 1;22(11):2108-21
references: 15169797
references: Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64
references: 11833496
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4519-27
references: 17671138
references: Gastroenterology. 2001 Feb;120(2):460-9
references: 11159886
references: Nat Rev Cancer. 2004 May;4(5):349-60
references: 15122206